Enwei Pharmaceutical Co., Ltd. (SHE:301331)

Enwei Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	871.66	808.19	781.2	687.5	675.79	630.97
Other Revenue	1.54	3.94	3.99	4.07	3.91	3.19
Revenue	873.2	812.13	785.19	691.57	679.7	634.16
Revenue Growth (YoY)	12.22%	3.43%	13.54%	1.75%	7.18%	2.17%
Cost of Revenue	444.41	404.17	384.36	346.2	298.67	271.75
Gross Profit	428.79	407.96	400.83	345.37	381.03	362.41
Selling, General & Admin	345.02	342.52	292.84	258.17	264.71	244.19
Research & Development	8.25	9.07	16.82	7.52	4.32	4.84
Other Operating Expenses	9.73	12.56	10.89	9.89	11.64	10.35
Operating Expenses	363.16	365.98	320.45	277.06	281.34	258.66
Operating Income	65.63	41.98	80.38	68.31	99.69	103.76
Interest Expense	-3.36	-2.43	-	-	-	-0.06
Interest & Investment Income	8.18	7.59	10.3	1.99	0.52	0.33
Other Non Operating Income (Expenses)	0.42	-0.08	-0.66	-0.27	-0.88	-2.16
EBT Excluding Unusual Items	70.86	47.07	90.03	70.03	99.33	101.87
Gain (Loss) on Sale of Investments	-	-	-	-	-0.44	-
Gain (Loss) on Sale of Assets	-0.4	-0.26	-0.04	-	-	0.01
Asset Writedown	0.62	-0.05	-	-	-0.01	-0.08
Other Unusual Items	-1.6	-0.06	11.33	11.83	20.25	22.67
Pretax Income	69.48	46.68	101.31	81.86	119.13	124.47
Income Tax Expense	11.57	9.19	15	14.06	17.39	19.29
Earnings From Continuing Operations	57.91	37.5	86.31	67.8	101.73	105.18
Minority Interest in Earnings	-	-	-	-	-	-6.44
Net Income	57.91	37.5	86.31	67.8	101.73	98.74
Net Income to Common	57.91	37.5	86.31	67.8	101.73	98.74
Net Income Growth	43.74%	-56.56%	27.30%	-33.36%	3.03%	19.55%
Shares Outstanding (Basic)	100	101	103	84	78	73
Shares Outstanding (Diluted)	100	101	103	84	78	73
Shares Change (YoY)	-2.14%	-1.82%	21.93%	8.34%	6.51%	-6.12%
EPS (Basic)	0.58	0.37	0.84	0.80	1.31	1.35
EPS (Diluted)	0.58	0.37	0.84	0.80	1.31	1.35
EPS Growth	46.89%	-55.75%	4.40%	-38.49%	-3.27%	27.35%
Free Cash Flow	9.05	28.69	-50.04	38.8	49.36	47.36
Free Cash Flow Per Share	0.09	0.28	-0.49	0.46	0.63	0.65
Dividend Per Share	0.180	0.180	0.540	1.600	-	0.875
Dividend Growth	-66.70%	-66.70%	-66.22%	-	-	53.33%
Gross Margin	49.10%	50.23%	51.05%	49.94%	56.06%	57.15%
Operating Margin	7.52%	5.17%	10.24%	9.88%	14.67%	16.36%
Profit Margin	6.63%	4.62%	10.99%	9.80%	14.97%	15.57%
Free Cash Flow Margin	1.04%	3.53%	-6.37%	5.61%	7.26%	7.47%
EBITDA	110.75	86.85	115.13	99.22	127.79	136.54
EBITDA Margin	12.68%	10.69%	14.66%	14.35%	18.80%	21.53%
D&A For EBITDA	45.13	44.87	34.75	30.91	28.1	32.79
EBIT	65.63	41.98	80.38	68.31	99.69	103.76
EBIT Margin	7.52%	5.17%	10.24%	9.88%	14.67%	16.36%
Effective Tax Rate	16.65%	19.68%	14.81%	17.18%	14.60%	15.50%
Revenue as Reported	689.72	812.13	785.19	691.57	679.7	634.16
Advertising Expenses	-	96.67	69.92	44.22	-	30.92

Source: S&P Global Market Intelligence. Standard template. Financial Sources.